Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company whose news flow is closely tied to the progress of its Superkine pipeline. Company updates consistently highlight advances in MDNA11, a long-acting IL-2 Superkine in the Phase 1/2 ABILITY-1 trial for advanced solid tumors, as well as developments in MDNA113, a tumor-anchored and conditionally activated PD-1 x IL-2 bifunctional Superkine, and bizaxofusp (MDNA55), an IL-4 Empowered Superkine for recurrent glioblastoma.
On this page, readers can follow MDNAF news related to clinical data readouts, new trial announcements and corporate milestones. Recent releases describe updated MDNA11 results in monotherapy and in combination with pembrolizumab, including activity in checkpoint inhibitor-resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H tumors, as well as plans to complete enrollment in ABILITY-1 and prepare for potential registrational studies. News also covers the NEO-CYT neoadjuvant trial in high-risk, surgically resectable Stage III melanoma, sponsored by Fondazione Melanoma Onlus, which will evaluate MDNA11 in combination with nivolumab with or without ipilimumab.
Investors and clinicians can also track preclinical and non-human primate updates for MDNA113, including safety and pharmacodynamic findings that Medicenna reports as supporting its advancement toward first-in-human trials. Additional news items address partnering efforts and data presentations for bizaxofusp in recurrent glioblastoma, patent issuances protecting IL-2 and IL-4 Superkine assets, and participation in scientific and investor conferences.
By reviewing the MDNAF news feed, users can see how Medicenna communicates new clinical results, outlines expected milestones, and provides context on the scientific rationale behind its Superkine programs, while also including standard cautions about the risks and uncertainties inherent in drug development.
Medicenna Therapeutics announced the presentation of two abstracts at the EORTC-NCI-AACR Virtual Scientific Program, scheduled for October 24-25, 2020. The first abstract discusses long-term survival results from the MDNA55-05 trial in recurrent glioblastoma multiforme, presented by Dr. John Sampson. The second abstract features updated pre-clinical data on MDNA11 and novel bi-specific IL-13 superkines, presented by Dr. Minh To. Both presentations will be available for on-demand viewing at Medicenna’s website after the event.
Medicenna Therapeutics (NASDAQ: MDNA) has received FDA approval for a hybrid registration trial design for its MDNA55 treatment targeting recurrent glioblastoma (rGBM). This innovative approach will use matched external controls for two-thirds of the control arm, reducing participant enrollment and trial costs while expediting regulatory approval. The design aims to generate robust overall survival data, potentially setting a new precedent for oncology trials. With previous promising results, the company looks to advance its partnership strategy for future development.